










































STAT2 deficiency and susceptibility to viral illness in humans
Citation for published version:
Hambleton, S, Goodbourn, S, Young, DF, Dickinson, P, Mohamad, SMB, Valappil, M, McGovern, N, Cant,
AJ, Hackett, SJ, Ghazal, P, Morgan, NV & Randall, RE 2013, 'STAT2 deficiency and susceptibility to viral
illness in humans' Proceedings of the National Academy of Sciences, vol 110, no. 8, pp. 3053-3058. DOI:
10.1073/pnas.1220098110
Digital Object Identifier (DOI):
10.1073/pnas.1220098110
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Proceedings of the National Academy of Sciences
Publisher Rights Statement:
Freely available online through the PNAS open access option.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 28. Apr. 2017
STAT2 deﬁciency and susceptibility to viral
illness in humans
Sophie Hambletona,b,1, Stephen Goodbournc, Dan F. Youngd, Paul Dickinsone, Siti M. B. Mohamada,f, Manoj Valappilg,
Naomi McGoverna, Andrew J. Canta,b, Scott J. Hacketth, Peter Ghazale, Neil V. Morgani, and Richard E. Randalld,1
aPrimary Immunodeﬁciency Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne NE2 4HH, United Kingdom; bPediatric
Immunology Service, Great North Children’s Hospital, Newcastle upon Tyne NE1 4LP, United Kingdom; cDivision of Biomedical Sciences, St. George’s,
University of London, London SW17 0RE, United Kingdom; dSchool of Biology, University of St. Andrews, Fife KY16 9TS, United Kingdom; eDivision of
Pathway Medicine, University of Edinburgh, Edinburgh, EH16 4SB, United Kingdom; fAdvanced Medical and Dental Institute, Universiti Sains Malaysia, 11800
USM Penang, Malaysia; gHealth Protection Agency, Royal Victoria Inﬁrmary, Newcastle upon Tyne NE1 4LP, United Kingdom; hPediatric Immunology
Department, Heartlands Hospital, Birmingham B9 5SS, United Kingdom; and iCentre for Cardiovascular Sciences, Institute for Biomedical Research, University
of Birmingham, Birmingham B15 2TT, United Kingdom
Edited* by Robert A. Lamb, Northwestern University, Evanston, IL, and approved January 10, 2013 (received for review November 22, 2012)
Severe infectious disease in children may be a manifestation of
primary immunodeﬁciency. These genetic disorders represent
important experiments of nature with the capacity to elucidate
nonredundant mechanisms of human immunity. We hypothesized
that a primary defect of innate antiviral immunity was responsible
for unusually severe viral illness in two siblings; the proband de-
veloped disseminated vaccine strain measles following routine
immunization, whereas an infant brother died after a 2-d febrile
illness from an unknown viral infection. Patient ﬁbroblasts were
indeed abnormally permissive for viral replication in vitro, associ-
ated with profound failure of type I IFN signaling and absence of
STAT2 protein. Sequencing of genomic DNA and RNA revealed
a homozygous mutation in intron 4 of STAT2 that prevented cor-
rect splicing in patient cells. Subsequently, other family members
were identiﬁed with the same genetic lesion. Despite documented
infection by known viral pathogens, some of which have been
more severe than normal, surviving STAT2-deﬁcient individuals
have remained generally healthy, with no obvious defects in their
adaptive immunity or developmental abnormalities. These ﬁnd-
ings imply that type I IFN signaling [through interferon-stimulated
gene factor 3 (ISGF3)] is surprisingly not essential for host defense
against the majority of common childhood viral infections.
measles vaccine | viruses | rare diseases
Innate immune responses play a key role in controlling micro-bial infections by interfering with the replication and/or via-
bility of the invading microbe, and favoring the development of
adaptive immunity. Foremost among innate antiviral defenses is
the IFN response. IFNs are a group of cytokines secreted as
a direct consequence of pathogen exposure, by most cell types
(innate IFN, types I and III) or by activated T and NK lym-
phocytes, in the context of an overall immune response (type II,
i.e., IFN-γ). The importance of IFN is emphasized by the fact
that most viruses have evolved strategies to evade this response
(1). Indeed, viruses generally lose pathogenicity when their de-
ﬁned IFN antagonists are knocked out. Furthermore, marked
susceptibility to viral infection has been observed in mice with
genetic lesions of the IFN signaling pathway [e.g., Ifnar1 (2), Stat1
(3, 4) or Stat2 (5)].
IFNs mediate their biological activity by up-regulating the
expression of hundreds of diverse IFN-stimulated genes (ISGs),
the products of which may have direct or indirect antiviral ac-
tivity. Most cell types can respond to type I IFN (as IFN-β and
multiple IFN-α subclasses) as well as IFN-γ, whereas there is
more limited tissue distribution of the receptor for type III IFN
(IFN-λ1, -λ2, and -λ3). Binding of IFN-α/β to the type I IFN
receptor (IFNAR) causes activation of the receptor-associated
kinases Jak1 and Tyk2, which in turn phosphorylate and activate
the signal transduction and activators of transcription STAT1 and
STAT2. These associate with IRF9 to form the heterotrimeric
transcription factor, ISGF3, that binds to IFN-stimulated response
elements (ISREs) to activate the promoter of IFN-α/β–stimulated
genes (6). Although type III IFNs bind to a distinct receptor, this
agonizes the same signaling pathway as IFNAR, and hence pro-
duces a similar transcriptional proﬁle (7). In contrast, ligation of
the IFN-γ receptor activates Jak1 and Jak2 to phosphorylate
STAT1 (but not STAT2), which homodimerizes to form the GAF
transcription factor that binds to GAS elements in the regulatory
regions of IFN-γ–induced genes. It should also be noted that
IFN-α/β also weakly activates GAF as a result of STAT1 phos-
phorylation; furthermore, certain ISGs can be induced by IRFs,
themselves activated by viral infection directly (8, 9) or following
IFN induction.
Primary immunodeﬁciency disorders (PIDs) provide an op-
portunity to scrutinize the importance of individual genes and
pathways in human immunity, yet isolated susceptibility to viral
infections has rarely been recognized as a PID phenotype (10,
11). Autosomal-recessive STAT1 deﬁciency in humans produces
a severe primary immunodeﬁciency characterized by suscepti-
bility to lethal viral and mycobacterial disease (12,13). In this
context, we now report the surprisingly mild phenotype of human
STAT2 deﬁciency. Despite a profoundly defective innate IFN
response, and evident susceptibility to some viral infections,
STAT2-deﬁcient individuals can cope well with the majority of
common viruses and lead a relatively healthy life.
Results
We evaluated a 5-y-old child with a history of disseminated vac-
cine-strain measles, a highly unusual complication despite wide-
spread vaccine use (14). Six days after routine vaccination aged
18 mo, the patient developed fever, rash, conjunctivitis, and
lymphadenopathy, followed by hepatitis and pneumonitis requir-
ing supplemental oxygen. Vaccine-strain measles was detected by
PCR in bronchoalveolar lavage and in blood as late as 14 d after
vaccination. This child recovered with supportive care, but an in-
fant sibling later died suddenly in the context of a 2-d febrile ill-
ness, with features of overwhelming viral infection postmortem.
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The presence of parental consanguinity further raised suspicion of
an autosomal recessive PID. However, no predisposition to bac-
terial infection in the proband was evident, and growth and de-
velopment were normal.
As neither history nor laboratory evaluation suggested a T- or
B-cell immunodeﬁciency (Table S1), we pursued the hypothesis
that a novel defect of innate immunity had produced this ap-
parently selective susceptibility to viral infection. As an initial
screen, we compared the ability of primary skin ﬁbroblasts from
the index patient and a healthy control subject to support viral
plaque formation in vitro (Fig. 1A). Strikingly, all the WT viruses
tested formed signiﬁcantly larger plaques on the patient’s cells
than the control cells, including inﬂuenza A virus and para-
inﬂuenza viruses. Furthermore, the attenuated vaccine strain of
measles could produce plaques on patient cells, in contrast to
control cells (Fig. 1A). These in vitro ﬁndings indeed suggested
an innate susceptibility to viral infection in the proband.
To explore this further, we used highly attenuated recombinant
strains of PIV5 (PIV5VΔC) and Bunyamwera virus (BUNΔNSs)
that lack deﬁned functional IFN antagonists (15, 16). These
viruses form pinpoint plaques (PIV5VΔC) or cannot form plaques
(BUNΔNSs) in cells that produce and respond to IFN (Fig. 1B),
but grow readily if the IFN system is disabled, for instance, by
engineering cells to express the V protein of PIV5 that targets
STAT1 for proteasome-mediated degradation (17, 18) (Fig. 1B;
see Fig. 4A for STAT1 deﬁciency and IFN-α–unresponsiveness of
V protein-expressing cells). Strikingly, patient cells supported the
formation of large plaques of PIV5VΔC and BUNΔNSs (Fig. 1B),
implying a complete failure of the type I IFN response.
To investigate the mechanism of this susceptibility, we ﬁrst
tested whether patient ﬁbroblasts could produce IFN in response
to virus infection (19). No impairment was observed in the
phosphorylation of IRF3 (Fig. 1C) or the subsequent production
of IFN (Fig. S1). We therefore compared the ability of patient and
control cells to develop an antiviral state in response to exogenous
IFN-α, challenging them with the same panel of viruses tested in
the plaque assays, and visualizing viral replication by immunoﬂu-
orescence (Fig. 1D). These results demonstrated a remarkable
lack of protection in the patient’s cells, establishing a severe defect
in their ability to respond to IFN-α.
To dissect this impaired IFN response, we used immunoblot-
ting to monitor the induction of selected ISGs in patient and
control ﬁbroblasts that were treated with IFN-α or IFN-γ, or
infected by virus (Fig. 2A). As expected, STAT1 was phosphor-
ylated and later induced by IFN-α and IFN-γ in the control cells,
and a similar result was seen in the patient’s cells (Fig. 2A and
Fig. S2), demonstrating intact GAF signaling downstream of
both IFN receptors. Although MxA and ISG56/IFIT1 were up-
regulated by IFN-α in the control cells, they were completely
refractory to induction in the patient cells, suggesting a block in
signaling via ISGF3. ISG56/IFIT1 could be induced upon in-
fection of patient cells with virus, consistent with the observation
that IRF3 activation was intact (Fig. 1C) and that IRF3 itself can
up-regulate ISG56 expression but not that of MxA (8, 9, 20).
Neither gene was up-regulated by IFN-γ.
To obtain a more global view of the response to IFN, we
undertook whole-genome transcriptional proﬁling of ﬁbroblasts
treated for 10 h in the presence or absence of IFN-α. In keeping
with the previously noted pattern, the IFN response of patient
cells was largely ablated in terms of the number of transcripts up-
regulated (∼10% of control; Fig. 2 B and C). Among the 284
genes that were up-regulated at least twofold in control cells but
not in patient cells, were many classical targets normally strongly
induced by IFN, e.g., Mx1, Mx2, OAS1, OAS2, and OAS3 (167-,
49-, 68-, 40-, and 30-fold induction in control cells, respectively).
The residual transcriptional response in patient cells, which
largely overlapped that of control (Fig. 2C), was blunted for
every gene except IRF1, suggesting partial activation (Fig. S3).
We therefore examined the promoter elements of the differen-
tially expressed genes for the presence of ISRE, GAS, and IRF1
binding sites by using the oPOSSUM database (21) (Fig. 2D).
The few ISRE-containing genes that were up-regulated by IFN-α
in patient cells also contained GAS elements and/or IRF1 sites,
and could thus have been up-regulated independently of ISGF3.
Given these results, we next examined the integrity of in-
dividual ISGF3 components in patient ﬁbroblasts (Fig. 3A).
Whereas IRF9 and STAT1 were readily detected, there was no
detectable expression of STAT2 as determined by immunoblot-
ting with antibodies against the C terminus (Fig. 3A) or N ter-
minus (Fig. S4). The complete lack of STAT2 provided a ready
explanation for the failure to induce ISGs dependent upon ac-
tivation by the ISGF3 complex. Genomic patient DNA was
therefore subjected to sequencing of the STAT2 gene, disclosing
WT sequence except for a single variant within the donor splice
site of introns 4 and 5 (c.381+5 G>C; Fig. 3B) that was absent
from databases of genetic variation (Ensembl release 67; Na-
tional Center for Biotechnology Information) and from 218
ethnically matched control chromosomes sequenced. Both af-
fected siblings were homozygous for this variant whereas the
parents and a healthy sibling (V5) were heterozygous (Fig. 3C).
G at position c.381+5 is highly conserved among STAT2 ortho-
logues from armadillo to mouse and apes, and its substitution by
C was predicted to destroy the donor splice site of intron 4 by three
alternative splicing prediction programs [Netgene2 (22), human
splicing ﬁnder 2.4.1 (23), and NNSPLICE 0.9 (24)]. We therefore
Fig. 1. Patient dermal ﬁbroblasts have a major defect in their IFN system.
(A) Relative plaque sizes of a panel of negative-strand RNA viruses [vaccine
strain measles virus (MeV), parainﬂuenza virus types 3 and 5 (PIV3, PIV5),
inﬂuenza A virus (FLUAV), respiratory syncytial virus (RSV), and Bunyamwera
virus (BUNV)] in patient and control cells. Monolayers of cells were virally
infected, and ﬁxed at 4 d postinfection (p.i.); plaques were visualized by
immunostaining. (B) Relative plaque sizes of IFN-sensitive viruses PIV5VΔC
and BUNΔNSs in control cells, those rendered IFN-unresponsive by forced
expression of PIV5-V (control/PIV5-V, see text), or patient cells. (C) Activation
(phosphorylation) of IRF3 in patient and control cells. Fibroblast monolayers
were or were not infected with the vM2 preparation of PIV5VΔC (19) in the
presence or absence of cycloheximide (CHX; 50 μg/mL). At 10 h p.i., cell
lysates were made and the presence of p-IRF3 detected by immunoblot
analysis. Note that more p-IRF3 is detected in the presence of CHX than in its
absence because activated IRF3 induces a ubiquitin ligase that targets p-IRF3
for proteasome-mediated degradation (9). (D) Monolayers of control and
patient cells were, or were not (Unt.), pretreated with IFN-α for 15 h before
infection with a panel of negative-sense RNA viruses at a multiplicity of in-
fection of 0.2 to 10 pfu/cell. At 48 h p.i., virus-infected cells were visualized
by immunoﬂuorescence.
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investigated the effect of the mutation on splicing of STAT2mRNA
by reverse transcriptase (RT)-PCR analysis of cDNA derived from
the index patient, family and control cells. To look in detail at the
splicing of intron 4, we performed a PCR with primers anchored in
exons 3 and 6, separated the reaction products by gel electro-
phoresis and sequenced individual bands (Fig. 3 D and E).
Whereas control cells produced a single band, corresponding to
fully spliced mRNA, two longer PCR products were obtained
from V.3, neither of which was correctly spliced. The larger
product retained intron 4 in its entirety, whereas a minor product
(similar in size to WT band) had been cryptically spliced and
retained 17 nt from intron 4. Heterozygous relatives generated
a mixture of all three bands, as expected.
In further analysis, we ampliﬁed full length STAT2mRNA from
V.3 and control by using primers anchored in the untranslated
leader and trailer sequences. The patient product was revealed to
be longer and less abundant than control, consistent with aberrant
splicing and presumably nonsense-mediated decay (Fig. S5). Se-
quencing revealed that the major full-length transcript in the pa-
tient retained intron 4 and intron 6 and lacked exons 16 and 17
Fig. 2. Patient cells fail to up-regulate ISGF3-dependent genes in response to IFN-α. (A) Control and patient skin ﬁbroblasts were treated for 18 h with IFN-α
or IFN-γ, infected with the vM2 preparation of PIV5VΔC for 18 h, or left untreated (Unt.). Total cell lysates were immunoblotted for STAT1, MxA, IFIT1/ISG56,
and actin. (B–D) Whole genome microarray analysis of the transcriptional response to IFN-α in control and patient cells. (B) Volcano plots show the effect of
IFN-α treatment of control and patient ﬁbroblasts for 10 h. Data are plotted for all 29,298 probes used (log2 fold change on the x axis, −log10-adjusted P value
on the y axis) to show signiﬁcance of expression change after treatment. Probes with at least twofold change (positively or negatively regulated) and adjusted
P ≤ 0.001 are shown in red; those not signiﬁcantly changed (i.e., less than twofold) are in black. (C) Venn diagram shows genes up-regulated in control and
patient cells following IFN-α treatment. Numbers of genes showing at least twofold change and adjusted P ≤ 0.001 cutoff are shown. Genes in control cells are
shown in gray, genes in patient cells are shown in red. (D) Venn diagrams to show numbers of differentially expressed genes with predicted binding sites for
the indicated transcription factors within 10,000 bp of their promoter. ISRE-containing genes are shown in red, IRF1 consensus binding site-containing genes
are shown in gray, and GAS-containing genes are shown in blue.
Fig. 3. Loss of ISGF3 activity reﬂects the absence of STAT2, caused by a homozygous splicing mutation in intron 4 of STAT2. (A) Total cell lysates of patient and
control cells that had, or had not (Unt.), been treated with IFN-α or IFN-γ for 18 h were immunoblotted for STAT1, STAT2, IRF9, and actin. (B) Capillary sequencing
traces from healthy control (Upper) and affected child V.3 (Lower) demonstrate homozygous G>C variant at position c.381+5. (C) Pedigree from a consan-
guineous family (roman numerals refer to the generation, numbers the individuals) with susceptibility to severe viral illness. Letters beneath family member
represent the genotype [i.e., homozygous (CC; ﬁlled boxes) or heterozygous (GC; half-ﬁlled boxes) for the G>C variant at position c.381+5; unﬁlled boxes indicate
unknown zygosity]. Proband is indicated by an arrow, line through V:4 indicates deceased. (D) Schematic showing exon structure of genomic DNA of STAT2
between exons 3 and 6. (E) Agarose gel electrophoresis of products obtained from RT-PCR by using primers anchored in exons 3 and 6 of STAT2 (indicated in D)
and template cDNA from the indicated family members or control, together with schematic showing mutant and natively spliced mRNA species.









as a result of splicing of exon 15 to a cryptic acceptor in intron
17, thus incorporating extra material 5′ to exon 18. This implies
unexpectedly long-range effects of the c.381+5 G>C mutation
on mRNA splicing. Readthrough into intron 4 would be pre-
dicted to result in a highly truncated protein, but, by immuno-
blotting with an antibody directed against the N terminus, we
were unable to demonstrate any such fragment of STAT2 in
patient cells (Fig. S4).
In the extended family, (pedigree is detailed Fig. 3C, in which
each member is coded with a roman numeral to designate their
generation and a number), we subsequently discovered three
further homozygotes for the c.381+5 G>C variant, including a 6-y-
old child (V.6) with a history of a prolonged febrile encephalitic
illness days after measles/mumps/rubella (MMR) vaccination.
Both she and V.7 (who had not been immunized for MMR) had
been hospitalized for viral illness on one other occasion, but
the recent infection history of their homozygous mother IV.3 was
unremarkable (childhood history was not available). We con-
ﬁrmed that homozygosity for the c.381+5 G>C mutation corre-
lated with the lack of STAT2 protein and an inability to up-
regulate MxA in response to IFN-α in leukocytes [i.e., peripheral
blood mononuclear cells (PBMCs)] obtained from the proband
(V3) and her aunt (IV:3), in contrast to the control and hetero-
zygous family members (IV:2, IV:4, and V5; Fig. S6). Thus,
STAT2 could not be detected, and MxA was not up-regulated by
IFN, in skin ﬁbroblasts or in PBMCs homozygous for the c.381+5
G>C variant, consistent with a pervasive defect in IFN signaling.
The conjunction of undetectable STAT2 expression, together
with profound unresponsiveness to IFN-α [as well as the inability
of PIV5 to target STAT1 for proteasome-mediated degradation
in the patient’s cells, a process that is absolutely dependent on
the presence of STAT2 (25); Fig. S7], implied that patient cells
were effectively STAT2-null. To establish beyond doubt that
deﬁciency of STAT2 was responsible for the in vitro suscepti-
bility phenotype, we transduced the patient ﬁbroblasts with
a lentiviral vector encoding WT STAT2 and documented the
restoration of type I IFN responsiveness, as indicated by both up-
regulation of antiviral ISGs (Fig. 4A) and resulting protection
against viral infection (Fig. 4 B and C).
Discussion
STAT2 c.381+5 G>C represents a splicing mutation, and our
virally susceptible patients exhibited this previously unreported
PID, STAT2 deﬁciency. Mutations within Stat2 in mice have
been linked to viral susceptibility in vivo and in vitro, considered
to reﬂect the nonredundant role of this molecule in signaling by
type I and type III IFNs. Stat2-null mice were reported to be
almost as vulnerable to vesicular stomatitis virus infection as
Stat1-null mice (5). In contrast, we ﬁnd the viral-susceptibility
phenotype of human STAT2 deﬁciency to be considerably milder
than has been described for children with autosomal-recessive
STAT1 deﬁciency (12, 13). The ﬁve cases of STAT2 deﬁciency
we report within this single kindred range in clinical phenotype
from asymptomatic (healthy adult) to fatal (death in infancy
from overwhelming viral illness). All three surviving affected
children have had hospital admissions for viral illness, and both
of those who received MMR vaccine became ill with deﬁnite
(V.3) or probable (V.6) dissemination of vaccine-strain virus.
However, other viral illnesses have generally been mild (Table S2
lists documented infection history and limited serology); for ex-
ample, three of the ﬁve have experienced unremarkable varicella
(the other surviving child remains varicella zoster virus-naive).
Furthermore the proband (V:3) experienced primary HSV in-
fection as gingivostomatitis, whereas one of the STAT1-deﬁcient
individuals described by Dupuis et al. died of HSV encephalitis
(12), and severe susceptibility to herpesviral disease appears
general in complete STAT1 deﬁciency (13). HSV encephalitis
susceptibility in humans has also been linked to mutations that
speciﬁcally impair viral IFN induction (26–29). The fact that
herpesvirus disease severity appears relatively normal in STAT2
deﬁciency implies that loss of ISGF3-dependent signaling is un-
likely to represent the sole mechanism for herpesviral suscepti-
bility in these disorders.
The particular patterns of susceptibility seen in these rare PIDs
must reﬂect the altered balance between host defenses and the
virulence and immune evasion strategies of those pathogens en-
countered (30). In this light, the evident virulence of vaccine strain
measles toward STAT2-deﬁcient individuals conﬁrms that IFN
sensitivity is critical to the attenuation of this virus, which displays
wider tissue tropism than its parent (31). On the host side, the
variable and age-dependent expressivity of the STAT2-deﬁcient
phenotype recalls the behavior of innate immune disorders affect-
ing TLR signaling pathways (26, 29, 32, 33). Although children with
the latter disorders are at high risk of invasive bacterial infection,
those who survive beyond childhood outgrow this susceptibility,
perhaps as a result of the development of adaptive immunity.
Our clinical and biochemical data suggest that GAF-dependent
signaling is functionally intact in STAT2 deﬁciency, not only within
the IL-12/IFN-γ pathway but also downstream of the IFNAR. This
ﬁnding is at odds with a previous report suggesting that STAT2 is
required to recruit STAT1 to the IFNAR, based on impairment
of STAT1 phosphorylation in a STAT2-deﬁcient cell line (34). In
Stat2-KO mice, however, Park et al. noted that this effect was
tissue-speciﬁc and reﬂected variable reduction in basal Stat1
expression (5). Similarly, we also noted reduced basal STAT1
expression in our STAT2-deﬁcient patient ﬁbroblasts (Figs. 2A
and 3A) that was corrected by STAT2 transduction (Fig. 4A).
This may reﬂect the operation of a STAT2-dependent autocrine
loop whereby constitutively expressed type I IFN contributes to
Fig. 4. Lentiviral transduction of STAT2 into patient cells restores their
ability to respond to IFN-α and induce an antiviral state. (A) Control and V:3
patient skin ﬁbroblasts, patient cells that had been genetically engineered
to express STAT2 (patient/STAT2), and control cells that expressed the
V protein of PIV5 (control/PIV5-V) that targets STAT1 for proteasome-me-
diated degradation (Fig. S7) were treated for 18 h with IFN-α or left un-
treated. Total cell lysates were immunoblotted for STAT1, STAT2, ISG56,
MxA, and actin. (B) Monolayers of patient and patient/STAT2 cells were, or
were not, pretreated with IFN-α for 15 h before mock infection (Uninf) or
infection with PIV5 at 10 pfu/cell. At 24 h p.i., virus-infected cells were vi-
sualized by immunoﬂuorescence. (C) Relative plaque size of PIV5VΔC in
unmodiﬁed patient cells and patient cells expressing STAT2. Monolayers of
cells were infected with PIV5VΔC, and ﬁxed at 4 d p.i.; plaques were visu-
alized by immunostaining.
3056 | www.pnas.org/cgi/doi/10.1073/pnas.1220098110 Hambleton et al.
maintenance of STAT1 expression (reviewed in ref. 35). None-
theless, our data show robust IFN-α–dependent phosphorylation
of STAT1 in patient cells (Fig. S2), suggesting that its re-
cruitment to the IFN-α/β receptor is independent of STAT2.
Naturally we cannot completely rule out the possibility that there
is a small amount of a N-terminally truncated form of STAT2—
which we failed to detect—that can perform this function.
Type I IFN exerts important effects within the adaptive im-
mune system, where it has been reported to modulate T-cell and
antigen-presenting cell behavior (36). However, the extent to
which this is STAT2-dependent is unclear, especially because
alternative IFN signaling pathways operate within different leu-
kocyte subsets (6, 37). Reduced splenic dendritic cell numbers
were noted in a Stat2-hypomorphic mouse strain (38), but we
found normal abundance of myeloid and plasmacytoid dendritic
cell as well as monocytes in peripheral blood of the index patient
(Fig. S8). Remarkably, the proband showed evidence of normal
adaptive immunity in positive antibody titers against live vaccines
(i.e., MMR), killed vaccines (i.e., tetanus, Haemophilus inﬂuen-
zae type b, pneumococcus), and naturally encountered pathogens
(i.e., inﬂuenza H1N1, adenovirus, and EBV; Table S2); she also
exhibited full suppression of EBV in peripheral blood. Hence, we
conclude that ISGF3-mediated IFN signaling is dispensable for
adaptive immunity in natura. Furthermore, even though ISGF3-
dependent induction of ISGs with direct antiviral activity (such as
MxA) clearly aids resistance to viral infections, it is by no means
essential for host defense against common viral pathogens in
humans. This is extremely surprising given the critical role of IFN
in the induction of an antiviral state in uninfected cells, thereby
slowing the spread of virus from the initial focus of infection.
Although many ISGs may be activated by other transcription
factors [including IRF1 (39)], such ISGF3-independent activation
usually occurs only within virally infected cells. Thus, recognition
of this unusual PID phenotype challenges understanding of the
concerted antiviral immune response and provides an important
model in which to deﬁne the role of innate IFN and its interaction
with viral pathogenesis in humans.
Materials and Methods
Cells. The studywas performedwith approval from theNational Research Ethics
Service. Clinical samples were obtained with informed consent according to the
Declaration of Helsinki. PBMCs and primary dermal ﬁbroblast cultures were
obtained by standard methods. The latter were cultured in DMEM with 10%
(vol/vol) FCS and supplemental penicillin and streptomycin. To generate con-
trol cells expressing the V protein of PIV5 and patient cells expressing func-
tional STAT2, the PIV5 V gene and the full-length ORF of STAT2 were cloned
into the bicistronic lentivirus vector (pHR-SIN-CSGW); lentiviruses were pro-
duced and the cells were transduced and selected for puromycin resistance as
described previously (40). The full-length ORF of human STAT2 was ampliﬁed
by using speciﬁc primers by reverse transcription (Superscript III; Invitrogen)
and PCR (HiFi DNA polymerase; Kappa Biosystems), using total RNA from
control patient ﬁbroblast cells. The insert was initially cloned into pJET1.2 and
sequenced, and then the insert was transferred into the lentivirus vector.
Viruses and Interferons. The viruses used have been described previously (41),
apart from measles virus, which was the Enders attenuated Edmonston
strain. IFN-α [Roferon A (Roche) or Intron A (Schering-Plough)] and IFN-γ (R &
D Systems; or Immukin (Boehringer)] were used at 1,000 IU/mL.
Plaque assays were performed by standard methods in six-well dishes that
included 0.1%Avicel (FMC Biopolymer) or 1%agarose (inﬂuenza A virus only;
Biogene) in the overlay medium. Plaques were visualized by immunostaining
by using a pool of monoclonal antibodies or polyclonal antisera speciﬁc for
the different viruses as described previously (41), together with alkaline
phosphatase-conjugated secondary antibody by using SIGMAFAST BCIP/NBT
as the substrate.
Immunoblotting and immunoﬂuorescence procedures for ﬁbroblasts have
previously been described (19). Virus-speciﬁc antibodies have been described
by Chen et al. (41). Antibodies speciﬁc for MxA, ISG56 (IFIT1), STAT1, C-ter-
minal STAT2, IRF3, and IRF9 were purchased from Santa Cruz (cat. nos.
sc50509, sc82946, sc417, sc476, sc9082, and sc496, respectively), pSTAT1 from
Upstate (nos. 07-302 and 07-307), p-IRF3 from Cell Signaling Technology (no.
4947), β-actin from Sigma (no. A 5441), and GAPDH from Abcam (no.
ab8245). Immunoﬂuorescence was examined with a Nikon Microphot-FXA
immunoﬂuorescence microscope.
PBMCs were seeded in a 24-well plate at 2 × 106 cells per well in 1 mL of
RPMI medium with 10% FCS, incubated at 37 °C in 5% CO2, and stimulated
with IFN-α overnight as described earlier. After harvesting by centrifugation,
cells were lysed in 20 mM Tris HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100,
5 mM EDTA, 100 mM DTT (Sigma-Aldrich), and NUPAGE LDS Sample Buffer
(Invitrogen). Lysates were subjected to electrophoresis and immunoblotting
as described earlier.
Mutation Screening. The 23 coding exons and exon–intron boundaries of
STAT2 were PCR-ampliﬁed with speciﬁc intronic primers designed using
exon-primer (http://ihg.gsf.de/ihg/ExonPrimer.html; primer sequences are
available on request). Sequencing was performed using standard methods
on an ABI 3730 automated sequencer (Applied Biosystems). Genomic DNA
from 218 ethnically matched controls was used to screen for the identiﬁed
STAT2 mutation.
RT-PCR. Total RNA was isolated from ﬁbroblasts by using Tri-Reagent (Sigma)
and used as a template for oligo-dT–primed reverse transcription using
SuperScript III (Invitrogen; Fig. S5). Aliquots of the RT reaction were used in
PCR ampliﬁcations with HiFi DNA polymerase (Kapa Biosystems) and the
following primers: for full-length ORF, STAT2 forward (5′-CCCCCATGGCG-
CAGTGGGAAATGCTG-3′) plus STAT2 reverse (5′-GGGGAATTCCTAGAAGTCA-
GAAGGCATC-3′); N-terminal fragment, STAT2 forward plus STAT2 SacLow
(5′-CAATGGGAGCTCTGATGCAGG-3′).
Alternatively, for exons 3 to 6, total RNA was extracted from human
PBMCs or ﬁbroblasts by using the RNeasy Mini Kit (Qiagen). cDNA was
synthesized by using random primers and AMV reverse transcriptase by
using Promega reverse transcription system A3500 according to the man-
ufacturer’s instructions. RT-PCR of exons 3 to 6 was performed by using the
following primers: STAT2_cDNAF (5′-CCAAGGCTACCATGCTATTC-3′) and
STAT2_cDNAR (5′-GCTGGTCTTTCAGTTGGCTG-3′).
Microarray Analysis. Patient (V:3) and control ﬁbroblasts were cultured in
DMEM containing 10% FCS in 24-well plates and treatedwith 1,000 U/mL IFN-α
for 10 h or given a mock treatment (n = 4). Cells were lysed with QIAgen
RLT plus buffer and RNA was isolated by using the QIAgen RNeasy Plus kit.
RNA concentration and purity were obtained by spectrophotometry, and
RNA integrity was monitored using a model 2100 Bioanalyzer system
(Agilent). Fifty nanograms of total RNA were used to synthesize biotinylated
cRNA target, which was hybridized to the Human PrimeView GeneChip
(Affymetrix) according to the manufacturer’s instructions. Data from hy-
bridized chips were acquired by using proprietary Affymetrix platform
scanners and AGCC software (Affymetrix). The numeric data were processed
and subsequently analyzed with the Bioconductor package (42) for the R
statistical programming environment. Raw data distributions and summary
statistics were assessed for quality. Data were then background-corrected,
quantile-normalized, and probe-set–summarized by using the RMA algo-
rithm (43). A nonspeciﬁc expression-level ﬁlter was applied to remove
probes that were not expressed on any of the samples in the experiment,
and the remaining 29,298 probes were used for statistical analysis. Null hy-
potheses for each probe were based on the comparison between mock and
IFN-α–treated samples; they were tested by using an empirical Bayes test,
providing good robustness for small sample sizes (44). To adjust for multiple
testing issues, the false discovery rate was controlled by using the Benja-
mini–Hochberg P value adjustment method (45). Probes were interpreted on
the basis of the fold change of differential expression between mock and
IFN-α treatment and the corresponding statistical signiﬁcance. Microarray
data have been deposited in the Gene Expression Omnibus database with
accession code GSE41960. Differentially expressed genes were analyzed for
overrepresented conserved transcription factor binding sites in the promoter
sequence (±10,000 bases) by single site analysis by using oPOSSUM database
3.0 (21) with a conservation cutoff of 0.4 and matrix score threshold of 85%.
Promoters were examined for the presence of ISGF3 (ISRE), IRF1, and STAT1
(GAS) binding sites.
Serologic Assessment of Adaptive Immunity. Serum antibody responses to
inﬂuenzaA(H1N1) pdm09, A(H3N3), and inﬂuenza B viruseswere detected by
hemagglutination inhibition assay (HI) by using previously describedmethods
(46). Samples with titers ≥32 by HI were considered positive. Antibody
responses to other natural and vaccine antigens were assessed by routine
diagnostic methods (adenovirus by complement ﬁxation, other antigens by
commercial ELISAs; details available on request).
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